I found an excellent article about the ASPS patient from Oregon on this trial, well written with the detailed descr. of the case overall. Of great interest is the reporting of the pseudoprogression after six doses - which is usually expected be occur in the beginning of the trial, first few doses.
Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment
https://www.sciencedirect.com/science/a ... 3318301687
"After six doses, she began to experience worsening headaches. Brain MRI confirmed enlargement of multiple brain metastases, most notably in the right temporal lobe (Fig. 1A-D) and right cerebellum, with extensive surrounding edema and 5-mm midline shift. Nineteen months prior, the temporal lobe lesion had been treated to 30 Gy and 5 months prior, to 20 Gy. The cerebellar lesion had been treated 13 months prior to 20 Gy. The patient then underwent uncomplicated diagnostic and therapeutic right temporal and cerebellar craniotomies for resection of these two lesions with 3 days of corticosteroids administered perioperatively. Upon pathologic review, no viable tumor was identified. The surgical specimens contained primarily necrotic tissue with extensive lymphocytic infiltrate as denoted by histology results of increase CD8 staining post-treatment"
They used contrast-enhanced MRI and were unable to find out that the mets were dead till they were resected as both enhancement and diameter were found as increased on the contrast-enhanced MRI.
Artcile about the ASPS case on a trial with pseudoprogression
Return to “TECENTRIQ (atezolizumab) by Genentech”
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance